DCF Group’s clients were responsible for nearly 50% of all capital raised by Boston Startups in February 2022
VC funding update: Boston-area startups that raised money in February
© 2024 DCF Group.
All Rights Reserved.
DCF Group is proud to have worked on 11 of the top 25 largest IPOs of 2021 in Massachusetts
2021 Massachusetts IPOs
DCF Group clients made up 50% of top ten 2021 VC deals in MA Biotech
5 DCF clients make the 2021 list of top 10 Venture Capital Deals in Massachusetts Biotech
DCF Group proudly worked on 7 of Fierce Biotech’s 2021 “Fierce 15”
Fierce Biotech has named their 2021 “Fierce 15”, which designates the most promising early-stage biotechnology companies in the industry.
Monte Rosa Therapeutics Announces Pricing of Initial Public Offering
Biotechnology Company, Monte Rosa Therapeutics, Inc., announced the pricing of its initial public offering of 11,700,000 shares of common stock .
DCF Group’s clients raised over 25% of all capital raised by Boston startups and tech firms in January 2021
VC funding update: Boston startups and tech firms raised $3.5B in January
DCF Group is proud to have worked on 3 of the top 10 Massachusetts Venture Capital deals of 2020
Top 10 Massachusetts VC Deals of 2020
Tessera Therapeutics Attracts Over $230M in Series B Financing
Tessera Therapeutics announced that it has raised over $230M in Series B financing to Advance ‘Gene Writing’ – A New Category in Genetic Medicine.
Cullinan Management Announces Pricing of Upsized Initial Public Offering
Cullinan Management announced the pricing of its upsized initial public offering of 11,900,000 shares of common stock.